PT  - JOURNAL ARTICLE
AU  - Sylvester, Bruce
ED  - Alexander, John H.
TI  - Promise and Problems Emerge for Oral Investigative Factor Xa Drug in Treating Acute Coronary Syndrome
DP  - 2008 Nov 01
TA  - MD Conference Express
PG  - 22--23
VI  - 8
IP  - 6
4099  - http://mdc.sagepub.com/content/8/6/22.short
4100  - http://mdc.sagepub.com/content/8/6/22.full
AB  - Treatment with investigative apixaban, an oral factor Xa inhibitor, shows promise as add-on protection against recurrent ischemic cardiovascular events among acute coronary syndrome patients who already are on standard antiplatelet therapy, including aspirin and clopidogrel. But dose-dependent bleeding remains an unresolved problem. This article discusses the Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose-Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome [APPRAISE-1; NCT00313300] trial.